<DOC>
	<DOCNO>NCT03086369</DOCNO>
	<brief_summary>The purpose study determine safety efficacy nab-paclitaxel gemcitabine without olaratumab treatment first-line metastatic pancreatic cancer .</brief_summary>
	<brief_title>A Study Nab-Paclitaxel Gemcitabine With Without Olaratumab ( LY3012207 ) Participants With Metastatic Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Histological cytological diagnosis adenocarcinoma exocrine pancreas metastatic ( Stage IV ) amenable resection curative intent . If present , clinically significant symptomatic amount ascites drain prior Day 1 . No prior line systemic therapy metastatic disease . Prior radiation therapy treatment cancer allow &lt; 25 % bone marrow . Phase 2 : archival tumor tissue willing provide pretreatment biopsy . Measurable nonmeasurable evaluable disease define Response Evaluation Criteria Solid Tumors ( RECIST 1.1 ) . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Discontinued previous treatment cancer â‰¥4 week prior . Adequate organ function . Life expectancy least 3 month . Serious concomitant systemic disorder . First line treatment metastatic pancreatic cancer . Received prior treatment FOLFOX FOLFIRINOX . Have know central nervous system malignancy metastasis . Current hematologic malignancy . Participated within last 30 day clinical trial . Women positive pregnancy test lactating . Have endocrine pancreatic tumor ampullary cancer . Currently enrol another clinical trial . History cancer unless complete remission treatment minimum 3 year . Known allergy nabpaclitaxel gemcitabine ingredient study drug formulation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>